


Economic Value of Novel Therapeutics for Primary Prevention of Cardiovascular Disease



Published on: February 09, 2026

Substantial health system value remains for reductions in adverse events and long-term complications.

In this Center for Pharmacoeconomics (CPE) Exclusive, we calculate value-informed price ranges and estimates of the societal benefit potentially generated by novel therapeutics used for primary prevention of CVD.

Bottom Line: Novel therapeutics for primary prevention of cardiovascular disease (CVD) that are able to reduce major adverse cardiovascular events (MACE) by 20-30% in a high-risk population (which is in line with the effect size recently reported for a PCSK9i in this population) could produce a value-informed price in the range of \$3,600-\$29,000 per year at a recently suggested threshold. Larger reductions in MACE would produce higher value-informed prices. A lower baseline risk of MACE would produce lower value-informed prices.

Purpose of Report: This report provides value-informed price ranges and estimates of the societal benefit potentially generated by novel therapeutics used for primary prevention of CVD. Within the report, value-informed price ranges and estimates of societal benefit are calculated assuming different levels of MACE reduction (from a 10% reduction in MACE to a 70% reduction in MACE), different cost-effectiveness analysis frameworks, different cost-effectiveness thresholds, and different levels of baseline risk for a MACE.

Key Economic Value Drivers: Much of the estimated economic value generated by novel therapeutics for primary prevention of CVD is the result of increased survival. Additionally, a generalized risk-adjusted cost-effectiveness analysis framework attributes more value to the novel therapeutic because it can capture the risk aversion from avoiding an infrequent but severe event like a MACE and the reduction in uncertainty around one's future health which are not well captured with conventional outcomes like the quality-adjusted life year.

Interpreting the Findings: We do not provide these estimates to suggest a price for a novel therapeutic or to make product-specific claims of cost-effectiveness, but rather to quantify potential health system and societal value, identify key drivers of health system and societal efficiency, suggest "novel" value elements that may influence the health economic value proposition, and provide a reference point for how a product might perform under different cost-effectiveness analysis frameworks and assumptions. This may be useful for companies and company builders as they think about evidence generation and the potential societal value of their products under development.

To discuss a specific novel therapeutic for the primary prevention of CVD with the Leerink Center for Pharmacoeconomics, please contact your Leerink representative.

Read our full report for more details and discussion.

The Leerink Center for Pharmacoeconomics is a division of MEDACorp and an affiliate of Leerink Partners

Leerink Center for Pharmacoeconomics

- Melanie Whittington, PhD, Managing Director, Head of the Center for Pharmacoeconomics

Contributors:



Melanie Whittington

Center for Pharmacoeconomics

Disclosures:

This information (including, but not limited to, prices, quotes, and statistics) has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and the information and any opinions contained herein are as of the date of this material and the Firm does not undertake any obligation to update them. The information is not an offer to sell or a solicitation to buy any product to which this information relates. Leerink Partners LLC (“Firm”), its officers, directors, employees, proprietary accounts, and affiliates may have a position, long or short, in the securities referred to in this report, and/or other related securities, and from time to time may increase or decrease the position or express a view that is contrary to that contained in this piece. The Firm’s research analysts, bankers, salespeople, and traders may provide oral or written market commentary or trading strategies that are contrary to opinions expressed, and the Firm’s market making desk may make investment decisions that are inconsistent with the opinions expressed in this document. The past performance of securities does not guarantee or predict future performance. This material does not take into account individual circumstances, objectives, or needs and is not intended as a recommendation to any particular person(s). As such, the financial instruments discussed herein may not be suitable for all investors, and investors must make their own investment decisions based upon their specific investment objectives and financial situation. This material is a marketing communication and is not and should not be construed as investment research or a research report prepared by a research analyst. Any views portrayed in this material may differ from those of the research department of Leerink Partners LLC. All information contained herein is intended solely for your own personal, informational use, and you are not permitted to reproduce, retransmit, disseminate, sell, license, distribute, republish, broadcast, post, circulate or commercially exploit the information in any manner or media without the express written consent of Leerink Partners LLC, or to use the information for any unlawful purpose. Additional information is available upon request by contacting the Editorial Department, Leerink Partners LLC, 53 State Street, 40th Floor, Boston, MA 02109. MEDACorp LLC (MEDACorp), an affiliate of Leerink Partners LLC, is a global network of independent healthcare professionals (Key Opinion Leaders and consultants) providing industry and market insights to Leerink Partners and its clients. © 2024 Leerink Partners LLC. All Rights Reserved. Member FINRA/SIPC